Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | GRM6 | O15303 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8493097 | 0.88 | CA12 (0.66) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27380062 | 0.83 | ALDH1A1 (0.59) | ALDH1A1HSD17B10KDM4EL3MBTL1MAPK1 | |
| SCHEMBL10562280 | 0.83 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2405060 | 0.83 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2339088 | 0.81 | CA12 (0.79) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29099717 | 0.81 | CA12 (0.79) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28281242 | 0.81 | CA12 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2894636 | 0.81 | ALDH1A1 (0.72) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4625495 | 0.81 | TSHR (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1188368 | 0.81 | CA12 (0.52) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101959404-B | Adenosine monophosphate activated protein kinase modulators | MERCURY THERAPEUTICS, INC. (US) | 2015-12-02 | — | — | CN | disclosed |
| US-20150266892-A1 | AMPK Modulators | MERCURY THERAPEUTICS INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266892-A1 | AMPK Modulators | MERCURY THERAPEUTICS INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266892-A1 | AMPK Modulators | MERCURY THERAPEUTICS INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-8980895-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980895-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980895-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120302576-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302576-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302576-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. | 2012-11-29 | — | — | US | disclosed |
| WO-2003047583-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BENZOFURANYL SUBSTITUTED 3-CYANOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SOLID TUMOURS | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003045395-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| WO-2002030924-A9 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
| WO-2001094341-A9 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2003-04-17 | — | — | WO | disclosed |
| EP-1292594-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | AstraZeneca AB (SE) | 2003-03-19 | — | — | EP | disclosed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | disclosed |
| WO-2001094341-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | WO | disclosed |
| EP-0805812-B1 | BICYCLIC SUBSTITUTED HEXAHYDROBENZ(E)ISOINDOLE ALPHA-1- ADRENERGIC ANTAGONISTS | ABBOTT LAB (US) | 2001-06-13 | — | — | EP | disclosed |
| US-5792767-A | TREATMENT OF BENIGN PROSTATIC HYPERTROPY | ABBOTT LABORATORIES (US) | 1998-08-11 | — | — | US | disclosed |
| US-5521181-A | Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists | ABBOTT LABORATORIES (US) | 1996-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266892-A1 | AMPK Modulators | PRKAG1, PRKAG2, PRKAG3 | CA12 4253/4885CA1 4462/4885CA2 2305/4885 |
| US-20120302576-A1 | AMPK MODULATORS | PRKAG1, PRKAG2, PRKAG3 | CA12 4253/4885CA1 4462/4885CA2 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.